Skip to NavigationSkip to content

Bausch Health buy bankrupt Synergy Pharmaceuticals for $200m

Published on 13/12/18 at 11:10am

Bankrupt drug developer Synergy Pharmaceuticals has announced that the company is to be acquired by Canadian speciality pharma firm Bausch Health for approximately $200 million in cash.

The New York-based company, who focused on drugs for constipation, will be sold to Bausch through a an auction to be carried out through a Chapter 11 bankruptcy filing, which allows businesses to sell themselves while being protected from creditors.

Synergy hope to wrap up the deal by the end of the first quarter of 2019. The deal would give Bausch the rights to Synergy’s once daily pill dolcanatide for use in treating both chronic idiopathic constipation and irritable bowel syndrome with constipation.

Court papers show that Synergy owes approximately $180 million to creditors. The company has been searching for a buyer since April 2015.

“Unfortunately, we have now reached a point where our financial challenges are preventing us from taking this important work to the next level," said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc."

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches